– Oxymatrine
Breakthrough for treatment
of Hepatitis C–

Oxymatrine is an alkaloid derived from the Chinese herb Kushen, Radix Sophorae. 500 kilos of herb is used to make 1 kilo of oxymatrine. This is the first product where we have seen Hepatitis C patients who are symptomatic feel radically better in a few days.

What is most pronounced in these Hepatitis C patients is the increase in energy level. In the coming months under the page Clinic News we will write-up all the blood tests, before and after oxymatrine as they get sent to us.

Oxymatrine has been studied in the treatment of hepatitis since 1998. At the end of the Oxymatrine Product Page we have listed all studies done on Hepatitis C recorded by PubMed, which is the website for the NIH and the National Library. Now with oxymatrine our ability to treat HCV has changed exponentially. Our track record in healing the liver, as evidenced by our performance by our patient's repeat biopsies has been stellar.

Yet our ability to directly kill the Hepatitis C virus lagged way behind our understanding of Hep C symptom patterns and how to treat them and facilitating liver regeneration. Now we feel that our protocol is far more complete in treating Hepatitis C.  This is also an excellent treatment for Hep B as well.

Hepatitis C

Hepatitis C is caused by a single-stranded RNA virus from the Flaviviridae family. It was discovered in 1989 by a team of researchers from Chiron Corporation headed by Daniel Bradley and Michael Houghton. The nature of the virus is best characterized by a comment Michael Houghton made in response to a question about the slow pace of drug research to combat HCV.

He replied, "It's because it is a small, moving target". HCV is a very small virus that has no mechanism to contain mutations. Consequently worldwide there are many different strains or genotypes that vary genetically from each other, some more virulent. Scientists have also been unable to propagate cell cultures or develop a non-primate animal model, which has also slowed down effective drug development. Worldwide it has been estimated that there are 170 million people chronically infected with HCV, as well as 4-5 million in the United States.

Transmission today is primarily through needle sharing. Prior to effective screening was implemented in 1990-92 blood transfusion was a major source of this infection as was the giving of clotting factors. Currently the risk of HCV infection in receiving a blood transfusion is less than 1 in a million. The use of vaccination guns in the Vietnam era, whereby multiple men were vaccinated from the same instrument was a major source of infection. Sexual transmission is rare and the CDC does not recommend condom use in monogamous couples, when one partner is infected.

Vertical transmission from mother to fetus runs about 5% and is much higher in mothers co-infected with HIV. Breast-feeding does not appear to be a source of infection. Any blood-to-blood contact can be a risk be it tattoos, sharing straws, razors, tooth brushes, finger nail clippers. HCV is not spread through casual contact such as hugging, kissing or sharing food or water.

Currently chronic liver diseases are the 10th most common cause of death in the USA with viral hepatitis the bulk of that stat. Disease progression is highly variable with constitution, genotype, toxic exposure, nutrition, drug and alcohol intake are all important considerations.

For more information on this product, click below.
Hepatitis C Powder Article 1, Hepatitis C Powder Article 2